Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

Fixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lymphoma, according to updated data from the phase 2 GO29781 trial.

Related Keywords

Canada ,Vancouver ,British Columbia ,United States ,United Kingdom ,American ,British ,Laurieh Sehn , ,International Conference On Malignant Lymphoma ,Bc Cancer Centre For Lymphoid ,University Of British Columbia ,American Society For Transplantation ,International Conference ,Lymphoid Cancer ,American Society ,Cellular Therapy ,Ann Arbor ,Mosunetuzumab ,Follicular Lymphoma ,Lymphoma ,Fixed Duration ,Complete Response ,Phase 2 Go29781 ,Icml ,Laurie Sehn Md ,